HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G $57 Bil. Gillette Acquisition Creates 21 Billion-Dollar Brand Portfolio

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble will acquire Gillette in a stock transaction valued at $57 bil., creating a consumer products powerhouse with combined sales of over $60 bil. and a portfolio that includes 21 billion-dollar brands, the two firms announced at a news conference in New York City Jan. 28

You may also be interested in...



Unilever Plan To Grow Consumer Health By Acquisition, Meet US Tightening Of Merger Scrutiny

Unilever, which has had three offers for GSK rebuffed, likely notes that the Federal Trade Commission and Department of Justice signal they will tighten scrutiny of deals that merge companies providing consumer-facing products and services.

Clash Of The Power Toothbrush Titans: P&G Challenges Philips' Sonicare Claims, Both Firms Appeal NAD Decision

Following its review of the two firms' latest clash over power brush claims, Council of Better Business Bureau's investigative division says Philips and P&G are appealing its recommendations within the industry self-regulation process.The recommendations were from a review conducted on the second challenge P&G made in a year on Philips' ads comparing the two firms' product.

Gillette Downsizes Tiger Woods' Marketing Role

Procter & Gamble/Gillette says it will curtail its use of golf superstar Tiger Woods in promotions

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel